Table 8.
Fenofibric acid + rosuvastatin 20 mg | |
---|---|
HDL-C n = 161 | |
Baseline mean (mg/dL) | 38.3 |
Final mean at 116 weeks (mg/dL) | 45.0 |
Mean percent change from baseline (%) ± SD | 19.2 ± 25.23 |
TG n = 161 | |
Baseline mean (mg/dL) | 294.5 |
Final mean at 116 weeks (mg/dL) | 137.5 |
Mean percent change from baseline (%) ± SD | −48.2 ± 22.61 |
LDL-C n = 159 | |
Baseline mean (mg/dL) | 152.5 |
Final mean at 116 weeks (mg/dL) | 87.0 |
Mean percent change from baseline (%) ± SD | −40.9 ± 20.66 |
Non-HDL-C n = 161 | |
Baseline mean (mg/dL) | 222.6 |
Final mean at 116 weeks (mg/dL) | 113.2 |
Mean percent change from baseline (%) ± SD | −48.6 ± 13.58 |
VLDL-C n = 152 | |
Baseline mean (mg/dL) | 71.4 |
Final mean at 116 weeks (mg/dL) | 26.6 |
Mean percent change from baseline (%) ± SD | −56.8 ± 25.17 |
Total-C n = 161 | |
Baseline mean (mg/dL) | 260.9 |
Final mean at 116 weeks (mg/dL) | 158.1 |
Mean percent change from baseline (%) ± SD | −38.7 ± 12.16 |
Abbreviations: HDL-C, high-density lipoprotein-cholesterol; TG, triglycerides; LDL-C, low-density lipoprotein-cholesterol; non-HDL-C, non high-density lipoprotein-cholesterol; VLDL-C, very-low density lipoprotein-cholesterol; total-C, total cholesterol.